- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05020457
SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.
January 30, 2024 updated by: Sichuan Baili Pharmaceutical Co., Ltd.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer
This multi-center, open label phase II clinical study is performed in patients with locally advanced or metastatic EGFR wild-type ALK wild-type non-small cell lung cancer progressed on prior anti-PD-1 mab ± platinum-based chemotherapy.
This study is investigating the safety and efficacy of SI-B001 at optimal combination dose with chemotherapy in patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hai Zhu
- Phone Number: +86-13980051002
- Email: zhuhai@baili-pharm.com
Study Contact Backup
- Name: Sa Xiao
- Phone Number: +86-15013238943
- Email: xiaosa@baili-pharm.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China
- Recruiting
- Chongqing University Cancer Hospital
-
Contact:
- Sixiong Wang
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- The Second Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Jiaquan Fan
-
Guangzhou, Guangdong, China, 510075
- Recruiting
- Sun Yat-sen University Cancer Center (SYSUCC)
-
Contact:
- Li Zhang
- Phone Number: 020-87343458
- Email: zhangli6@mail.sysu.edu.cn
-
-
Guangxi Zhuang Autonomous Region
-
Guilin, Guangxi Zhuang Autonomous Region, China
- Recruiting
- The Second Affiliated Hospital of Guilin Medical University
-
Contact:
- Bihui Li
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Shandong Cancer Hospital
-
Contact:
- Qisen Guo
-
-
Zhejiang
-
Taizhou, Zhejiang, China
- Recruiting
- Taizhou Hospital of Zhejiang Province
-
Contact:
- Dongqing Lv
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily sign informed consent forms and follow program requirements;
- Male or female;
- Age: ≥ 18 years;
- Expected survival time ≥ 3 months;
- Patients with locally advanced or metastatic EGFR wild-type ALK wild-type lung cancer, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody, disease progression or intolerance after first-line treatment with anti-PD-1/PD-L1 antibody and platinum-based chemotherapy, or progression or intolerance after first-line treatment with anti-PD-1/PD-L1 monoclonal antibody;
- The subject agrees to provide archival tumor tissue samples or fresh tissue samples of the primary tumor or metastases within 6 months; if the subject is unable to provide tumor tissue samples and the subject is unable to provide the gene sequencing report, the subject shall agree to complete the ctDNA EGFR detection during the screening period, and can be assessed by the investigator if other inclusion criteria are met;
- Must have at least one measurable lesion as defined by RECISTv1.1;
- Performance status score ECOG0 or 1;
- Toxicities from prior anticancer therapy have recovered to grade ≤ 2 as defined by NCI-CTCAEv5.0 (except alopecia);
- No severe cardiac dysfunction, left ventricular score ≥ 50%;
The level of organ function must meet the following criteria:
- Bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 × 109/L, platelet count ≥ 80 × 109/L, hemoglobin ≥ 90 g/L;
- Liver function: TBIL ≤ 1.5ULN (total bilirubin ≤ 3ULN for subjects with Gilbert's syndrome, liver cancer or liver metastases); AST and ALT ≤ 2.5ULN for subjects without liver metastases; AST and ALT ≤ 5.0ULN for subjects with liver metastases;
- Renal function: creatinine (Cr) ≤ 1.5ULN, or creatinine clearance (Ccr) ≥ 50 mL/min (according to CockcroftandGault formula).
- Coagulation function: international normalized ratio (INR) ≤ 1.5 × ULN, and activated partial thromboplastin time (APTT) ≤ 1.5ULN;
- Urine protein ≤ 2 + (measured by dipstick) or < 1000 mg/24 h (urine);
- Premenopausal women of childbearing potential must have a negative serum or urine pregnancy test 7 before starting treatment and must be non-lactating; all patients (male or female) should take adequate barrier contraception measures throughout the treatment cycle and 6 months after the end of treatment.
Exclusion Criteria:
- Patients with past use of docetaxel;
- Prior to signing the informed consent, the gene sequencing or ctDNA testing report of the previous tissue samples indicated the presence of MET 14 exon jump positive, ROS1 rearrangement positive, BRAF V600E mutation positive, NTRK fusion positive, RET rearrangement positive, HER2 mutation positive, HER2 amplification positive, Patients with KRAS G12C mutation positive;
- Chemotherapy, biotherapy, immunotherapy, radical radiotherapy, and major surgery were used within 4 weeks before the first administration; palliative radiotherapy, targeted therapy (including small-molecule tyrosine kinase inhibitors) and other antitumor therapy were used within 2 weeks;
- Screening the history of severe heart disease within the first six months, such as: symptomatic congestive heart failure (CHF) ≥2 (CTCAE v5.0) history, New York Heart Society (NYHA) ≥2 heart failure, acute coronary syndrome, etc.;
- Prolonged QT interval (QTc > 450 msec in men or 470 msec in women), complete left bundle branch block, and Degree III atrioventricular block;
- Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, except for type I diabetes, hypothyroidism controllable by replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis);
- Other malignancies diagnosed within 5 years prior to first dose,Exceptions include: radical basal cell carcinoma of the skin, scaly cell carcinoma of the skin, and/or radical resection of carcinoma in situ;
- Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
- Pulmonary disease defined as ≥ grade 3 according to CTCAEv5.0, including resting dyspnea, or requiring continuous oxygen therapy, or patients with a history of interstitial lung disease (ILD);
- Symptoms of active central nervous system metastases.However, patients with stable parenchymal metastases can be stable, and whether it is stable or not is judged by the investigator;
- Patients with a history of hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or hypersensitivity to SI-B001 or any of the excipient components of Osimertinib;
- History of autologous or allogeneic stem cell transplantation;
- In previous anthracycline (neo) adjuvant therapy, the cumulative dose of anthracycline was > 360 mg/m2;
- Human immunodeficiency virus antibody (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > 104) or hepatitis C virus (HCV) infection;
- Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.;
- Received other unmarketed clinical study drugs or treatments within 4 weeks prior to study participation;
- Other conditions for trial participation were not considered by the investigator to be appropriate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SI-B001 combined with AP or TP_A
SI-B001 combined with Platinum-based chemotherapy(AP or TP).
Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant after first-line treatment with anti-PD-1 /L1 mab alone.
|
SI-B001 is administered by intravenous drip once weekly (QW).
120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
AP or TP should be administered immediately after SI-B001 is completed.
The administration of AP or TP should refer to the drug instructions and standard usage.
Other Names:
|
Experimental: SI-B001 combined with Docetaxel_B
Patients with EGFRwt/ALKwt non-small cell lung cancer were included and progressed or were intolerant after first-line treatment with platinum-based two-drug chemotherapy plus anti-PD-1 /L1 mab.
|
SI-B001 is administered by intravenous drip once weekly (QW).
120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
Docetaxel should be administered immediately after SI-B001 is completed.
The administration of Docetaxel should refer to the drug instructions and standard usage.
|
Experimental: SI-B001 combined with Docetaxel_C
Patients enrolled with EGFRwt/ALKwt NSCLC progressed or were intolerant to treatment with anti-PD-1 /PD-L1 monoclonal antibody after first-line or above chemotherapy.
|
SI-B001 is administered by intravenous drip once weekly (QW).
120 min ± 10 min after the first intravenous drip, if the infusion reaction is tolerable during the first dose, the subsequent infusion can be completed within 60-120 min (unless agreed or required by the investigator, the infusion time can be extended), if SI-B001 and chemotherapy are used on the same day, the infusion of chemotherapeutic drugs should be continued after the completion of SI-B001 infusion.
Docetaxel should be administered immediately after SI-B001 is completed.
The administration of Docetaxel should refer to the drug instructions and standard usage.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Up to approximately 24 months
|
Objective Response Rate
|
Up to approximately 24 months
|
Optimal combination dose (only IIa)
Time Frame: Up to approximately 24 months
|
Optimal combination dose of SI-B001 with chemotherapy (only IIa)
|
Up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DOR
Time Frame: Up to approximately 24 months
|
Duration of Response
|
Up to approximately 24 months
|
OS
Time Frame: Up to approximately 24 months
|
Overall Survival
|
Up to approximately 24 months
|
TEAE
Time Frame: Up to approximately 24 months
|
Treatment Emergent Adverse Events
|
Up to approximately 24 months
|
Cmax
Time Frame: Up to approximately 24 months
|
Maximum serum concentration
|
Up to approximately 24 months
|
Tmax
Time Frame: Up to approximately 24 months
|
Time to maximum serum concentration
|
Up to approximately 24 months
|
Ctrough
Time Frame: Up to approximately 24 months
|
Minimum serum concentration
|
Up to approximately 24 months
|
ADA
Time Frame: Up to approximately 24 months
|
anti-SI-B001 antibody
|
Up to approximately 24 months
|
DCR
Time Frame: Up to approximately 24 months
|
Disease Control Rate
|
Up to approximately 24 months
|
PFS
Time Frame: Up to approximately 24 months
|
Progression Free Survival
|
Up to approximately 24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Li Zhang, Sun Yat-sen University Cancer Center (SYSUCC)
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 7, 2021
Primary Completion (Estimated)
April 1, 2024
Study Completion (Estimated)
April 1, 2024
Study Registration Dates
First Submitted
August 22, 2021
First Submitted That Met QC Criteria
August 22, 2021
First Posted (Actual)
August 25, 2021
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Folic Acid Antagonists
- Docetaxel
- Paclitaxel
- Cisplatin
- Pemetrexed
Other Study ID Numbers
- SI-B001_201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
Clinical Trials on SI-B001
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingHead and Neck Squamous Cell CarcinomaChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingSquamous Cell Carcinoma of Head and NeckChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.RecruitingLocally Advanced or Metastatic Epithelial TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingSquamous Cell Carcinoma of Lung | Non-small Cell Lung AdenocarcinomaChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingNon-small Cell Lung CancerChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingEsophageal Squamous Cell CarcinomasChina
-
Sichuan Baili Pharmaceutical Co., Ltd.Terminated
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingHead and Neck Squamous Cell CarcinomaChina
-
HK inno.N CorporationUnknownHand, Foot and Mouth DiseaseKorea, Republic of